INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Inari Medical, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 12, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Inari touted its "record revenues" based on "the strength in our core VTE business." In fact, the Company was spending significant sums to improperly compensate medical professionals for using its products. The Company was compensating health care professionals in violation of federal Anti-Kickback Statute and Civil False Claims Act. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Inari, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.